Is ABBV Stock (ABBV) a Buy Ahead of Q2 Earnings?

AbbVie (ABBV) is anticipated to report Q2 earnings with Wall Street expecting EPS of $2.95 (+11.3% YoY) and revenues of $15.04 billion (+4% YoY), continuing its trend of often exceeding estimates. Growth is projected to be driven by strong sales of newer immunology drugs Skyrizi and Rinvoq, alongside neuroscience products like Vraylar, Ubrelvy, and Qulipta. These gains are critical to offset anticipated revenue declines from its blockbuster Humira post-patent expiration and Imbruvica due to increased competition. Strategically, AbbVie is expanding into new therapeutic areas such as obesity and oncology through significant investments and licensing deals, contributing to the stock's over 10% year-to-date rise and its current 'Moderate Buy' analyst consensus.

Analysis

AbbVie is approaching its Q2 earnings report with Wall Street forecasting an 11.3% year-over-year increase in EPS to $2.95 and a 4% rise in revenue to $15.04 billion. The company has a demonstrated history of surpassing such estimates, as evidenced in Q1 when it beat adjusted EPS guidance by $0.10 and revenue expectations by nearly $550 million. The primary driver for Q2 growth is expected to be the continued commercial success of its newer immunology drugs, Skyrizi and Rinvoq, along with neuroscience assets like Vraylar, Ubrelvy, and Qulipta, which collectively powered the ex-Humira platform to over 21% sales growth last quarter. This performance is critical as it must offset the persistent decline in revenue from the blockbuster drug Humira, which lost patent exclusivity in 2023, and from the oncology drug Imbruvica, which faces heightened competition. Strategically, AbbVie is actively building its future pipeline through a licensing deal for a trispecific antibody and a significant $10 billion investment to expand into high-growth areas like obesity. This forward-looking strategy, coupled with a stock price that has risen over 10% year-to-date, underpins a 'Moderate Buy' analyst consensus and a consensus price target of $209.33, implying a 9.47% potential upside.

Key Decisions for Investors

• Investors should closely scrutinize the upcoming Q2 report to verify that growth from Skyrizi, Rinvoq, and the neuroscience portfolio is robust enough to compensate for the well-understood declines in Humira and Imbruvica revenues.
• Given the stock's strong year-to-date performance and a consistent track record of earnings beats, holding positions into the earnings release is supported by the current 'Moderate Buy' consensus and implied price target upside.
• Long-term oriented investors should assess management's commentary on the progress of strategic initiatives, particularly the $10 billion investment in new areas like obesity, as these are crucial for future value creation beyond the current product portfolio.